Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 25, 2019

Transplant reports positive results in kidney device trial

Transplant Biomedicals has reported positive interim results of the first-in-human clinical trial of the Vivian device in kidney transplantation.

Transplant Biomedicals has reported positive interim results of the first-in-human clinical trial of the Vivian device in kidney transplantation.

For the multi-centre, prospective, single-arm EMERGE trial, the company enrolled a total of 32 patients who received a kidney from either brain death standard and extended criteria donors (DBD; SCD+ECD) or cardiac arrest donors (DCD MIII).

The trial has been designed to evaluate the safety and performance of the Vivian device for organ preservation in donor kidneys for transplantation.

Transplant Biomedicals completed patient enrolment for the trial in April this year.

The results highlighted an excellent safety profile and no events related with the device were reported.

The device was also associated with a low rate of delayed graft function (DGF) at 30-days with a short duration of DGF.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Transplant Biomedicals co-founder and CSO Dr Carmen Peralta said: “These results are in full alignment with our pre-clinical experience and fully support the idea that our disrupting platform that combines hypothermia and low frequency/energy ultrasounds can play a relevant role in addressing the current unmet medical needs not covered by the standard-of-care in solid organ preservation, static cold storage.”

The proportion of recipients with DGF in the primary performance endpoint was 19%.

In the DBD and DCD subgroups, the rate of DGF was 25% and 16%, respectively.

Transplant Biomedicals CEO Dr Joan Salgado said: “These interim results in kidney transplantation represent a boost to our mission of improving the outcomes in solid organ transplantation and to continue and accelerate further our development activities in cell and tissue preservation.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU